Company Overview
Masimo Corporation engages in the global development, manufacture, and marketing of patient monitoring technologies, alongside automation and connectivity solutions. The company operates within the Healthcare sector, specifically the Medical Devices industry, where it supplies critical monitoring equipment for clinical environments. As of the latest available data, the enterprise holds a market capitalization of $9.60B and reports trailing twelve-month revenue of $1.53B while employing approximately 2,200 individuals. These financial figures indicate that Masimo operates as a significant player in the medical technology landscape, with a valuation that reflects substantial market confidence despite the high cost of capital inherent in the healthcare device sector. The scale of operations, supported by a workforce of 2,200 employees, suggests a mature organization capable of sustaining extensive research and development efforts required to maintain technological leadership in pulse oximetry and signal extraction technologies.
Financial Health
The company generated $1.53B in revenue over the trailing twelve months, resulting in a net income of $207.70M and an EBITDA of $345.30M. The gap between the $1.53B revenue and the $207.70M net income reveals a cost structure where approximately 13.18% of revenue is lost to expenses, taxes, and interest before reaching the bottom line. Free cash flow stands at $316.41M, which provides the company with significant financial flexibility to fund operations, service debt obligations, or pursue strategic acquisitions without requiring external equity financing. The gross margin is reported at 61.8%, indicating strong pricing power and efficient manufacturing costs relative to sales. The operating margin of 18.5% demonstrates effective control over overhead and administrative expenses, whereas the profit margin of -9.9% highlights a specific discrepancy in how net income is calculated relative to the reported revenue and EBITDA in this reporting period. On the balance sheet, total cash of $152.30M is compared against total debt of $559.30M, resulting in a debt-to-equity ratio of 77.55. This leverage ratio suggests the company utilizes a leveraged balance sheet structure, relying heavily on equity to support its debt obligations rather than maintaining a conservative, debt-free position. The current ratio of 2.49 indicates robust short-term liquidity, as current assets are more than double current liabilities, ensuring the ability to meet immediate financial obligations. Return on Equity is 23.4% and Return on Assets is 8.9%, metrics that reveal management effectiveness in generating returns for shareholders relative to the equity invested and the total asset base utilized.
Valuation Assessment
The trailing P/E ratio is 46.78, while the forward P/E is 27.21. The substantial difference between these two metrics implies that the market expects a significant improvement in earnings trajectory over the next twelve months, potentially driven by upcoming product cycles or operational efficiencies. The price-to-book ratio stands at 12.91, which indicates a substantial market premium over the company's book value, suggesting investors are willing to pay a high multiple for the intangible assets and future growth potential associated with Masimo's intellectual property. The price-to-sales ratio is 6.29, and the EV/EBITDA multiple is 28.19; these alternative valuation metrics suggest the market values the company based on its sales generation capability and earnings before interest, taxes, depreciation, and amortization, rather than just current earnings per share. The 52-week high is $178.85 and the 52-week low is $125.94, providing a historical range against which current trading levels can be assessed. While the exact current price is not explicitly provided as a single variable to calculate a percentage, the trading range demonstrates a volatility of over 40% within the last year, with the stock capable of moving significantly from its lows to its highs. The beta value is 1.25, which explains that the stock price exhibits higher volatility relative to the broader market, tending to amplify market movements by 25% compared to a standard market index.
Growth & Income
Revenue growth year-over-year is 12.0%, while earnings growth year-over-year is listed as N/A in the available data. The absence of a reported earnings growth figure relative to the positive revenue growth implies that profitability metrics may be subject to unique accounting adjustments or temporary cost fluctuations that decouple earnings from revenue expansion in this specific reporting cycle. Since the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders. This non-dividend status indicates that Masimo reinvests all generated earnings directly back into the business to fund research and development, manufacturing expansion, or debt reduction rather than paying cash returns. The overall growth and income profile is characterized by strong top-line expansion of 12.0% and a capital allocation strategy focused entirely on internal reinvestment rather than shareholder distributions, reflecting a growth-oriented business model typical of high-potential medical device manufacturers.